LoginSignup
image de profil
Anderlé MPoint@Anderle
5J
Looks quite reasonable $NWRN:

+ EV / Sales (5.29)
+ Gross Margin TTM (98.26%)
+ Rule-of-40 Score TTM (432.88%)
+ Sales Growth TTM (467.18%)
+ PEG TTM (0.04)
+ Return on equity LJ (1086.63%)
+ EBIT margin LJ (50.93%)

- Debt ratio (34.68)
- Equity ratio LJ (2.28%) ✌🏻
•
2
•
image de profil
PiHu@PiHu
5J
@Anderle huhu, where did you get the data so quickly? :)
•
1
•
image de profil
Anderlé MPoint@Anderle
5J
@PiHu I'm registered at https://aktien.guide/ (premium account) I think the site is really great and very clear ✌🏻
•
3
•
Sam M.@Sam_Mumm
5J
@Anderle There is always the risk that Evenamide will not be approved and then the price will plummet.
•
1
•
image de profil
Anderlé MPoint@Anderle
5J
@Sam_Mumm Correct, the risk exists for all pharmaceutical and biotechnology companies.
•
2
•